Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mario, Falcini"'
Autor:
Prosperini, Luca, De Rossi, Nicola, Scarpazza, Cristina, Moiola, Lucia, Cosottini, Mirco, Gerevini, Simonetta, Capra, Ruggero, the Italian PML study group, Maria Pia Amato, Artusi, Carlo Alberto, Fabio, Bandini, Antonio, Bertolotto, Vincenzo, Bresciamorra, Guido, Cavaletti, Paolacavalla, Marco, Capobianco, Clerico, Marinella, Eleonora, Cocco, Giangaetano, D'Aleo, Marilena de Riz, Luciano, Deotto, Durelli, Luca, Mario, Falcini, Eugenio, Ferrari, Maria Luisa Fusco, Claudio, Gasperini, Simonetta, Gerevini, Angelo, Ghezzi, Luigi, Grimaldi, Mario, Guidotti, Alessandra, Lugaresi, Maria Giovanna Marrosu, Lucia, Moiola, Paola, Naldi, Patrizia, Perrone, Matteo, Pizzorno, Carlo, Pozzilli, Monica, Rezzonico, Marco, Rovaris, Giuseppe, Salemi, Marco, Salvetti, Giuseppe, Santuccio, Elio, Scarpini, Edoardo, Sessa, Claudio, Solaro, Giulia, Tabiadon, Carla, Tortorella, Maria, Trojano, Paola, Valentino
Publikováno v:
PLoS ONE, Vol 11, Iss 12, p e0168376 (2016)
PLoS ONE
PLoS ONE
Background The monoclonal antibody natalizumab (NTZ) is a highly effective treatment for patients with multiple sclerosis (MS). However, this drug is associated with increased risk of developing Progressive Multifocal Leukoencephalopathy (PML), an op
Autor:
Pietro Annovazzi, Francesco Patti, Lucia Moiola, Mario Falcini, Antonio Uccelli, A. Ghezzi, Vittorio Martinelli, Marco Capobianco, Aurora Fuiani, Jessica Frau, Carla Tortorella, Paola Perini, Giacomo Lus, Giancarlo Comi, Diego Centonze, Luca Prosperini
Rituximab (RTX) efficacy in NMO is suggested by several case series. No consensus exists on optimal dosing strategies. At present the treatment schedules more frequently used are 375 mg/m2/week iv for 4 weeks (RTX-A) and 1000 mg iv twice, 2 weeks apa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::525768c15089872f7a99899dad952251
http://hdl.handle.net/11573/899874
http://hdl.handle.net/11573/899874
Publikováno v:
Journal of the Neurological Sciences. 131:177-182
The aim of this 7-year inception cohort study was to determine the prognostic value of plateaux in cognitive decline in the course of Alzheimer's disease (AD) as well as their impact on the rate of progression of cognitive impairment. From a consecut
Autor:
Marina Del Puppo, Alessandra Vella, Antonio Giorgio, Antonio Federico, Maria Teresa Dotti, Mario Falcini, Gian Nicola Gallus, Andrea Mignarri, Angelo Vattimo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e08e78a20042c466e9dfb6fd6696cc6
http://hdl.handle.net/10281/28829
http://hdl.handle.net/10281/28829
Autor:
Mario Falcini, Tiziana Biagioli, S. Lori, Elisa Bizzoco, Anna Maria Repice, Patrizia Nencini, Alessandro Barilaro, Annalisa Vinattieri, Luca Massacesi, Sabrina Matà, R. Taiuti, Francesco Lolli, Bahia Hakiki, Maria Pia Amato, Gianfranco Siracusa, Marco Moretti
Publikováno v:
Journal of neurology. 256(11)
Neuromyelitis optica spectrum disorder (NMOsd) is a group of demyelinating disorders recently redefined and associated with NMO-IgG/anti-aquaporin 4 antibodies. Because NMOsd is of unknown prevalence worldwide, we conducted a retrospective, cross-sec
Publikováno v:
Parkinsonism & Related Disorders. 18:998-999
Publikováno v:
International Journal of Gynecology & Obstetrics. 114:81-82
Autor:
Laura Bracco, Luigi Amaducci, Claudio Fonda, Carolina Piccini, Gianna Manfredi, Mario Falcini
Publikováno v:
Alzheimer disease and associated disorders. 13(3)
We sought to identify the most reliable magnetic resonance (MR) measures for the diagnosis and staging of Alzheimer disease (AD) in a clinical setting and to estimate, for different degrees of dementia, the rate of change of cerebral atrophy in certa